{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:35:37Z","timestamp":1761561337825},"reference-count":37,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,5,8]],"date-time":"2009-05-08T00:00:00Z","timestamp":1241740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Reports have described a decrease in glomerular filtration rate (eGFR) associated with tenofovir disoproxil fumarate (TDF) use in HIV positive individuals. However, no study has examined renal function over a prolonged period in HIV\/hepatitis B virus (HBV) co\u2010infected patients. We assessed the long\u2010term durability and toxicity of TDF in a cohort of 39 e antigen (eAg) positive co\u2010infected patients commenced on TDF 245\u2003mg daily either in addition to or as part of standard antiretroviral therapy. Immunological and virological parameters were followed to 260\u2003weeks, with the median follow\u2010up period being 251\u2003weeks (range 69\u2013290\u2003weeks). eGFR was calculated using the Modification in Diet in Renal Disease equation. On treatment at 260\u2003weeks, 88% (14\/16) had HIV viral load &lt;50 copies\/mL, median CD4 count rose from 318 to 532 cells\/mm<jats:sup>3<\/jats:sup>, median alanine aminotransferase (ALT) fell from 61\u2003IU\/L to 42\u2003IU\/L, with 35% (7\/20) having a normal ALT, median HBV DNA fell from 69\u2003\u00d7\u200310<jats:sup>6<\/jats:sup> copies\/mL to 500 copies\/mL, with 75% (12\/16) having an undetectable HBV DNA level and 55% (6\/11) becoming eAg negative. Of those with detectable HBV DNA, none had TDF resistance mutations. The eGFR declined by 22.19\u2003mL\/min\/1.73\u2003mm<jats:sup>2<\/jats:sup> from baseline (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.023) over this period, which was unaffected by protease inhibitor use, baseline CD4 count, ALT or HBV DNA level. Three patients discontinued TDF therapy due to renal dysfunction. In conclusion, TDF has sustained efficacy but is associated with a significant decline in eGFR. Further larger studies are required to clarify this observation.<\/jats:p>","DOI":"10.1111\/j.1365-2893.2009.01084.x","type":"journal-article","created":{"date-parts":[[2009,5,8]],"date-time":"2009-05-08T09:39:37Z","timestamp":1241775577000},"page":"471-478","source":"Crossref","is-referenced-by-count":16,"title":["Reduced glomerular filtration rate but sustained virologic response in HIV\/hepatitis B co\u2010infected individuals on long\u2010term tenofovir"],"prefix":"10.1111","volume":"16","author":[{"given":"L. K. K.","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Gilleece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mandalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Murungi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,6,10]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"World Health Organisation.Hepatitis B.WHO 2002.http:\/\/www.who.int\/csr\/disease\/hepatitis\/HepatitisB_whocdscsrlyo2002_2.pdf(accessed 24 September 2007)."},{"key":"e_1_2_7_3_2","unstructured":"UNAIDS.Report on the global HIV\/AIDS epidemic2008.http:\/\/data.unaids.org\/pub\/GlobalReport\/2008\/JC1510_2008GlobalReport_en.zip(accessed 1st October 2008)."},{"key":"e_1_2_7_4_2","volume-title":"HIV\/AIDS Treatment and Care. Clinical Protocols for the WHO European","author":"World Health Organisation","year":"2007"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-39951"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21627"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2005.0311b.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2000.00192.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200301030-00002"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21055"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/378068"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/368314"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000138983.45235.02"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000242830.27990.93"},{"key":"e_1_2_7_15_2","article-title":"Tenofovir in the treatment of Hepatitis b\/HIV co\u2010infected individuals [Abstract]","volume":"15","author":"Gilleece Y","year":"2004","journal-title":"Int Conf AIDS"},{"key":"e_1_2_7_16_2","first-page":"A0828","article-title":"A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]","volume":"11","author":"Levey AS","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-2-200307150-00013"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f8b46f"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200211220-00023"},{"key":"e_1_2_7_20_2","article-title":"Tenofovir disoproxil fumarate suppresses lamivudine\u2010resistant HBV replication in patients coinfected with HIV\/HBV [Abstract]","author":"Bochet M","year":"2002","journal-title":"9th Conference on Retroviruses and Opportunistic Infection, Seattle"},{"key":"e_1_2_7_21_2","article-title":"Anti\u2010HBV activity of tenofovir disoproxil fumarate in lamivudine\u2010experienced HIV\/HBV coinfected patients [Abstract]","author":"Cooper D","year":"2002","journal-title":"9th Conference on Retroviruses and Opportunistic Infections, Seattle"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/345770"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/380398"},{"key":"e_1_2_7_24_2","volume-title":"3rd International Workshop on HIV and Hepatitis Co\u2010infection, Paris","author":"Mauss S","year":"2007"},{"issue":"6","key":"e_1_2_7_25_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/135965350501000612","article-title":"Selection of hepatitis B virus polymerase mutations in HIV\u2010coinfected patients treated with tenofovir","volume":"10","author":"Sheldon J","year":"2005","journal-title":"Antivir Ther"},{"key":"e_1_2_7_26_2","volume-title":"14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA","author":"Fux C","year":"2007"},{"key":"e_1_2_7_27_2","volume-title":"14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA","author":"Moore R","year":"2007"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280b07b33"},{"key":"e_1_2_7_29_2","volume-title":"14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA","author":"Goicoechea M","year":"2007"},{"key":"e_1_2_7_30_2","volume-title":"14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA","author":"Wai H","year":"2007"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000210610.52836.07"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282ef1bb4"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000220165.79736.d3"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00232.x"},{"issue":"1","key":"e_1_2_7_35_2","first-page":"11","article-title":"Hepatorenal syndrome","volume":"28","author":"Ng CK","year":"2007","journal-title":"Clin Biochem Rev"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01340406"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-007-0088-x"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.0525144"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2893.2009.01084.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2893.2009.01084.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T01:29:40Z","timestamp":1697074180000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2893.2009.01084.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,10]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1111\/j.1365-2893.2009.01084.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2893.2009.01084.x","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,10]]}}}